NCT01801930View on ClinicalTrials.gov

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Colorectal Cancer
Interventions
DRUG

OCV-103 and OCV-104

0.3 mg of each

DRUG

OCV-103 and OCV-104

1 mg of each

DRUG

OCV-103 and OCV-104

3 mg of each

DRUG

OCV-103 and OCV-104

6 mg of each

Trial Locations (3)

Unknown

Nagoya

Sunto-gun

Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY